Johnson & Johnson (JNJ)
NYSE: JNJ · Pharmaceutical Preparations · New Brunswick, NJ · filing with the SEC since 1994
Grade6.5
◀ Past 7.6● Present 7.0▶ Future 4.9
Who owns Johnson & Johnson
As filed with the SECHolders of 5% or more
1
Vanguard Capital Management holds 7.49% of Common Stock, as its SCHEDULE 13G filed May 1, 2026 says.
Directors and officers
23
report now, of 47 people on the record since 2006. Their holdings as a group are not read here.
Institutions as a whole
n/a
The record does not read the share held by managers that file Form 13F, so none is printed and no split of the rest is estimated. What it holds is the 1 named at left.
Holders of 5% or moreshare of the class, as filed
Vanguard Capital Management
SCHEDULE 13G · filed May 1, 2026 · Common Stock
The Vanguard Group
SCHEDULE 13G/A · filed Mar 26, 2026 · Common Stock · reported falling below 5%, from 10.1% in Feb 5, 2026
What JNJ reports owning in othersstakes of 5% or more, and other ties
CVRx, Inc. CVRX
SCHEDULE 13G/A · filed Jan 12, 2026 · Common Stock, $0.01 par value
Rapport Therapeutics, Inc. RAPP
SCHEDULE 13G/A · filed Oct 22, 2025 · Common Stock, $0.001 par value · reported falling below 5%
Rallybio Corporation RLYB
SCHEDULE 13G/A · filed Apr 13, 2026 · Common Stock, $0.0001 par value · reported falling below 5%
Other ties the annual report names
Kenvue Inc.
An entity · legal entity · owns, named in the 10-K filed Feb 11, 2026
Intra-Cellular Therapies, Inc.
A company bought · acquisition · Mar 2025 · owns, named in the 10-K filed Feb 11, 2026
Proteologix
A company bought · acquisition · Jun 2024 · owns, named in the 10-K filed Feb 11, 2026
Shockwave Medical, Inc.
A company bought · acquisition · May 2024 · owns, named in the 10-K filed Feb 11, 2026
Ambrx
A company bought · acquisition · Feb 2024 · owns, named in the 10-K filed Feb 11, 2026
Halda Therapeutics
A company bought · acquisition · owns, named in the 10-K filed Feb 11, 2026
400 subsidiaries in 73 countries, from the list filed with the 10-K filed Feb 11, 2026. Its Form 13F-HR for Sep 30, 2026 lists 15 holdings. The record carries no value for them.
Insider tradesForm 4
29sales
1purchases
0sales on a scheduled plan
10people selling
$155Msold, in dollars
$300,000bought, in dollars
Open-market trades on Form 4 from Sep 30, 2025 to Sep 30, 2026. A scheduled plan is a selling program set in advance under SEC rule 10b5-1. The trades are listed as filed and do not feed the grade.
By calendar yearSoldBought
2026 runs to Sep 30, 2026. Dollars as filed, summed by the transaction date.
People who traded in the window11 of 47 on the roster
| Person | Role as filed | Sales | Sold | On a plan | Buys | Bought |
|---|---|---|---|---|---|---|
| Duato Joaquin | CEO and Chairman of the Board | 6 | $66.8M | 0 | 0 | $0 |
| Wolk Joseph J | Exec VP, CFO | 4 | $21.8M | 0 | 0 | $0 |
| Reed John C | EVP, Innovative Medicine, R&D | 4 | $17.3M | 0 | 0 | $0 |
| Schmid Timothy | EVP, WW Chair, MedTech | 5 | $15.1M | 0 | 0 | $0 |
| Swanson James D. | EVP, CIO | 3 | $15.1M | 0 | 0 | $0 |
| Broadhurst Vanessa | EVP, Global Corp Affairs | 2 | $7.3M | 0 | 0 | $0 |
| Forminard Elizabeth | EVP, Chief Legal Officer | 2 | $4.1M | 0 | 0 | $0 |
| Taubert Jennifer L | EVP, WWC. Innovative Medicine | 1 | $4.0M | 0 | 0 | $0 |
| Wengel Kathryn E | EVP, Chief TO and Risk Officer | 1 | $2.4M | 0 | 0 | $0 |
| Decker Robert J | VP Corporate Controller | 1 | $1.0M | 0 | 0 | $0 |
| Morikis John G | director | 0 | $0 | 0 | 1 | $300,000 |